Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How would you treat newly diagnosed metastatic HER2 positive breast cancer with liquid NGS revealed ERBB2 L755S mutation (a marker for resistance against trastuzumab)?
Answer from: Medical Oncologist at Community Practice
Neratinib
Sign in or Register to read more
19471
Related Questions
What is your approach to treatment in hormone receptor positive, HER2 negative (0 IHC) metastatic breast cancer with ERBB2 gene amplification after progression on AI and fulvestrant CDK4/6i with visceral crisis?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Would you consider a PARP inhibitor in metastatic TNBC with high LOH on NGS?
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?
How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?
How do you treat metastatic breast cancer which is HR positive, Her2 negative with PIK3CA+ and high tumor mutational burden (>10) who progressed after prior ET+CDK 4/6 and PIK3CA inhibitor therapy?
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
When should paclitaxel (or other chemo) be discontinued in de novo metastatic triple negative breast cancer with high PDL1 in favor of continuing pembrolizumab alone with good treatment response?